Please type a plus sign (+) inside this box →

Signature

or /25/energe of persons

Approved for use through 10/31/2002. OMB 0651-0032 U.S. Patent and Trademark Office US DEPARTMENT OF COMMERCE

Date

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

Attorney Docket No 16336.002 UTILITY First Inventor PATENT APPLICATION **VIVIEN W. CHAN TRANSMITTAL** Title GENE PRODUCTS DIFFERENTIALLY EXPRESSED UN CANCEROUS COLON CELLS AND THEIR METHODS (Only for new nonprovisional applications under 37 CFR 1.53(b)) Express Mail Label No. EL 779 660 531 US Assistant Commissioner for Patents **APPLICATION ELEMENTS Box Patent Application** ADDRESS TO: Washington, DC 20231 SEE MPEP chapter 600 concerning utility patent application contents Fee Transmittal Form (e.g., PTO/SB/17) CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix) Nucleotide and/or Amino Acid Sequence Submission Applicant claims small entity status fif applicable, all necessary) See 37 CFR 1 27 Computer Readable Form (CRF) [Total Pages 393] b. Specification Sequence Listing on з. 🖂 Specification i. . X CD-ROM or CD-R (2 copies), or -Descriptive title of the invention -Cross Reference to Related Applications п. . П paper -Statement Regarding Fed sponsored R & D -Reference to sequence listing, a table, c. Statements verifying identity of above copies or a computer program listing appendix -Background of the Invention ACCOMPANYING APPLICATION PARTS -Brief Summary of the Invention -Brief Description of the Drawings (if filed) -Detailed Description 9. Assignment Papers (cover sheet & documents(s)) -Claim(s) -Abstract of the Disclosure 37 CFR 3.73(b) Statement Power of Attorney (when there is an assignee) Drawing(s) (35 U.S.C. 113) [Total Pages: ___ English Translation Document (if applicable) [Total Pages: _ 5. Oath or Declaration Information Disclosure Copies of IDS Citations a. . Newly executed (original or copy) Statement (IDS)/PTO-1449 b. Copy from a prior application (37 CFR 1.63 (d)) **Preliminary Amendment** (for continuation/divisional with Box 18 completed) Return Receipt Postcard (MPEP 503) (Should be specifically itemized) **DELETION OF INVENTOR(S)** Certified Copy of Priority Document(s) Signed statement attached deleting inventor(s) (if foreign priority is claimed) Named in the prior application, see 37 CFR 1 63(d)(2) and 1.33(b) Nonpublication Request under 35 U S C. 122 (b)(2)(B)(i). Applicant must attach form PTO/SB/35 6. 🛛 Application Data Sheet See 37 CFR 1.76 or its equivalent Other. 18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76; _ Continuation Divisional Continuation-in-part (CIP) of prior application No.: ___ Prior application information: Examiner: Group Art Unit: For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts. 19. CORRESPONDENCE ADDRESS 24353 or Correspondence address below Customer Number or Bar Code Label (Insert Customer No or Attach bar code label here) Name Carol L. Francis **BOZICEVIC, FIELD & FRANCIS LLP** 200 Middlefleld Road, Suite 200 Address Zıp 94025 State Callfornia City Menlo Park Code Telephone (650) 327-3400 Fax (650) 327-3231 Country U.S.A. Registration No. (Attorney/Agent) 36,513 Carol L. Francis Name

Burden Hour Statement This form is estimated to take 2 bours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

CERTIFICATION REGARDING SEQUENCE LISTING

Application Number	Unassigned
Confirmation Number	N/A
Filing Date	Herewith (February 21, 2002)
First Named Inventor	Vivien W. Chan et al.
Examiner	Unassigned
Group Art	Unassigned
Attorney Docket No.	16336.002

ADDRESS TO:

Assistant Commissioner for Patents

Washington, D.C. 20231

As required by 37 § C.F.R. 1.821(f), all information on CD 'Copy 1', 'Copy 2' and 'CRF' is identical. I hereby certify that the enclosed submission includes no new matter. The Sequence Listing was prepared with the software FASTSEQ, and conforms to the Patent Office guidelines.

Applicant respectfully submits that the subject application is in adherence to 37 CFR §§ 1.821-1.825.

The Commissioner is hereby authorized to charge any underpayment of fees associated with this communication, including any necessary fees for extensions of time, or credit any overpayment to Deposit Account No. 50-0815, order number 16336.002.

The Commissioner is authorized to charge any fees which may be required, or credit any overpayment to Deposit Account 50-0815, Order No. 16336.002. If additional fees are required, including extensions of time, please consider this a petition therefore.

Name (Print/Type)	Carol L. Francis	11	Regis	tration No.	36,513	
Signature	Carof)	jana	Date		02-21-2002	
Firm Name	Bozicevic, Field & Fyar	ncis LLP	Address	200 Mide	200 Middlefield Road, Suite 200	
City	Menlo Park	State	California	zip	94025	
Telephone - Direct Dial	650-833-7713		Facsimile	650-327	-3231	
EXPRESS MAIL LABEL NO. 779 660 531 US						

EXPRESS MAIL LABEL NO. EL 779 660 531 US

NONPUBLICATION REQUEST	First Named Inventor	Vivien W. Chan	
UNDER	Atty Docket Number	16336.002	
35 U.S.C. 122(b)(2)(B)(i)	Title: "GENE PRODUCTS DIFFERENTIALLY EXPRESSED IN CANCEROUS COLON CELLS AND THEIR METHODS OF USE"		

I hereby certify that the invention disclosed in the attached application has not and will not be the subject of an application filed in another country, or under a multilateral agreement, that requires publication at eighteen months after filing.

I hereby request that the attached application not be published under 35 U.S.C. 122(b).

Digitatare

Carol L. Francis

Typed or Printed Name

This request must be signed in compliance with 37 CFR 1.33(b) and submitted with the application **upon filing.**

Applicant may rescind this nonpublication request at any time. If applicant rescinds a request that an application not be published under 35 U.S.C. 122(b), the application will be scheduled for publication at eighteen months from the earliest claimed filing date for which a benefit is claimed.

If applicant subsequently files an application directed to the invention disclosed in the attached application in another country, or under a multilateral international agreement, that requires publication of applications eighteen months after filing, the applicant must notify the United States Patent and Trademark Office of such filing within forty-five (45) days after the date of the filing of such foreign or international application. Failure to do so will result in abandonment of this application (35 U.S.C. 122(b)(2)(B)(iii)).